Novel NIR-II fluorescent probes for biliary atresia imaging
Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is...
Ausführliche Beschreibung
Autor*in: |
Xiaodong Zeng [verfasserIn] Yuqin Liao [verfasserIn] Xue Qiao [verfasserIn] Ke Liang [verfasserIn] Qiusi Luo [verfasserIn] Mingbo Deng [verfasserIn] Yishen Liu [verfasserIn] Weijing Zhang [verfasserIn] Xuechuan Hong [verfasserIn] Yuling Xiao [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Acta Pharmaceutica Sinica B - Elsevier, 2013, 13(2023), 11, Seite 4578-4590 |
---|---|
Übergeordnetes Werk: |
volume:13 ; year:2023 ; number:11 ; pages:4578-4590 |
Links: |
---|
DOI / URN: |
10.1016/j.apsb.2023.07.005 |
---|
Katalog-ID: |
DOAJ09682509X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ09682509X | ||
003 | DE-627 | ||
005 | 20240413162815.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240413s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.apsb.2023.07.005 |2 doi | |
035 | |a (DE-627)DOAJ09682509X | ||
035 | |a (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
100 | 0 | |a Xiaodong Zeng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel NIR-II fluorescent probes for biliary atresia imaging |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. | ||
650 | 4 | |a Biliary atresia | |
650 | 4 | |a Fluorescence imaging | |
650 | 4 | |a Second near-infrared window | |
650 | 4 | |a Early diagnosis | |
650 | 4 | |a Hepatobiliary excretion | |
653 | 0 | |a Therapeutics. Pharmacology | |
700 | 0 | |a Yuqin Liao |e verfasserin |4 aut | |
700 | 0 | |a Xue Qiao |e verfasserin |4 aut | |
700 | 0 | |a Ke Liang |e verfasserin |4 aut | |
700 | 0 | |a Qiusi Luo |e verfasserin |4 aut | |
700 | 0 | |a Mingbo Deng |e verfasserin |4 aut | |
700 | 0 | |a Yishen Liu |e verfasserin |4 aut | |
700 | 0 | |a Weijing Zhang |e verfasserin |4 aut | |
700 | 0 | |a Xuechuan Hong |e verfasserin |4 aut | |
700 | 0 | |a Yuling Xiao |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Acta Pharmaceutica Sinica B |d Elsevier, 2013 |g 13(2023), 11, Seite 4578-4590 |w (DE-627)670211095 |w (DE-600)2631779-5 |x 22113843 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2023 |g number:11 |g pages:4578-4590 |
856 | 4 | 0 | |u https://doi.org/10.1016/j.apsb.2023.07.005 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 |z kostenfrei |
856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2211383523002551 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2211-3835 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 13 |j 2023 |e 11 |h 4578-4590 |
author_variant |
x z xz y l yl x q xq k l kl q l ql m d md y l yl w z wz x h xh y x yx |
---|---|
matchkey_str |
article:22113843:2023----::oenriloecnpoefriir |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RM |
publishDate |
2023 |
allfields |
10.1016/j.apsb.2023.07.005 doi (DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 DE-627 ger DE-627 rakwb eng RM1-950 Xiaodong Zeng verfasserin aut Novel NIR-II fluorescent probes for biliary atresia imaging 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology Yuqin Liao verfasserin aut Xue Qiao verfasserin aut Ke Liang verfasserin aut Qiusi Luo verfasserin aut Mingbo Deng verfasserin aut Yishen Liu verfasserin aut Weijing Zhang verfasserin aut Xuechuan Hong verfasserin aut Yuling Xiao verfasserin aut In Acta Pharmaceutica Sinica B Elsevier, 2013 13(2023), 11, Seite 4578-4590 (DE-627)670211095 (DE-600)2631779-5 22113843 nnns volume:13 year:2023 number:11 pages:4578-4590 https://doi.org/10.1016/j.apsb.2023.07.005 kostenfrei https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 kostenfrei http://www.sciencedirect.com/science/article/pii/S2211383523002551 kostenfrei https://doaj.org/toc/2211-3835 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2023 11 4578-4590 |
spelling |
10.1016/j.apsb.2023.07.005 doi (DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 DE-627 ger DE-627 rakwb eng RM1-950 Xiaodong Zeng verfasserin aut Novel NIR-II fluorescent probes for biliary atresia imaging 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology Yuqin Liao verfasserin aut Xue Qiao verfasserin aut Ke Liang verfasserin aut Qiusi Luo verfasserin aut Mingbo Deng verfasserin aut Yishen Liu verfasserin aut Weijing Zhang verfasserin aut Xuechuan Hong verfasserin aut Yuling Xiao verfasserin aut In Acta Pharmaceutica Sinica B Elsevier, 2013 13(2023), 11, Seite 4578-4590 (DE-627)670211095 (DE-600)2631779-5 22113843 nnns volume:13 year:2023 number:11 pages:4578-4590 https://doi.org/10.1016/j.apsb.2023.07.005 kostenfrei https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 kostenfrei http://www.sciencedirect.com/science/article/pii/S2211383523002551 kostenfrei https://doaj.org/toc/2211-3835 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2023 11 4578-4590 |
allfields_unstemmed |
10.1016/j.apsb.2023.07.005 doi (DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 DE-627 ger DE-627 rakwb eng RM1-950 Xiaodong Zeng verfasserin aut Novel NIR-II fluorescent probes for biliary atresia imaging 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology Yuqin Liao verfasserin aut Xue Qiao verfasserin aut Ke Liang verfasserin aut Qiusi Luo verfasserin aut Mingbo Deng verfasserin aut Yishen Liu verfasserin aut Weijing Zhang verfasserin aut Xuechuan Hong verfasserin aut Yuling Xiao verfasserin aut In Acta Pharmaceutica Sinica B Elsevier, 2013 13(2023), 11, Seite 4578-4590 (DE-627)670211095 (DE-600)2631779-5 22113843 nnns volume:13 year:2023 number:11 pages:4578-4590 https://doi.org/10.1016/j.apsb.2023.07.005 kostenfrei https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 kostenfrei http://www.sciencedirect.com/science/article/pii/S2211383523002551 kostenfrei https://doaj.org/toc/2211-3835 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2023 11 4578-4590 |
allfieldsGer |
10.1016/j.apsb.2023.07.005 doi (DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 DE-627 ger DE-627 rakwb eng RM1-950 Xiaodong Zeng verfasserin aut Novel NIR-II fluorescent probes for biliary atresia imaging 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology Yuqin Liao verfasserin aut Xue Qiao verfasserin aut Ke Liang verfasserin aut Qiusi Luo verfasserin aut Mingbo Deng verfasserin aut Yishen Liu verfasserin aut Weijing Zhang verfasserin aut Xuechuan Hong verfasserin aut Yuling Xiao verfasserin aut In Acta Pharmaceutica Sinica B Elsevier, 2013 13(2023), 11, Seite 4578-4590 (DE-627)670211095 (DE-600)2631779-5 22113843 nnns volume:13 year:2023 number:11 pages:4578-4590 https://doi.org/10.1016/j.apsb.2023.07.005 kostenfrei https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 kostenfrei http://www.sciencedirect.com/science/article/pii/S2211383523002551 kostenfrei https://doaj.org/toc/2211-3835 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2023 11 4578-4590 |
allfieldsSound |
10.1016/j.apsb.2023.07.005 doi (DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 DE-627 ger DE-627 rakwb eng RM1-950 Xiaodong Zeng verfasserin aut Novel NIR-II fluorescent probes for biliary atresia imaging 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology Yuqin Liao verfasserin aut Xue Qiao verfasserin aut Ke Liang verfasserin aut Qiusi Luo verfasserin aut Mingbo Deng verfasserin aut Yishen Liu verfasserin aut Weijing Zhang verfasserin aut Xuechuan Hong verfasserin aut Yuling Xiao verfasserin aut In Acta Pharmaceutica Sinica B Elsevier, 2013 13(2023), 11, Seite 4578-4590 (DE-627)670211095 (DE-600)2631779-5 22113843 nnns volume:13 year:2023 number:11 pages:4578-4590 https://doi.org/10.1016/j.apsb.2023.07.005 kostenfrei https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 kostenfrei http://www.sciencedirect.com/science/article/pii/S2211383523002551 kostenfrei https://doaj.org/toc/2211-3835 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 13 2023 11 4578-4590 |
language |
English |
source |
In Acta Pharmaceutica Sinica B 13(2023), 11, Seite 4578-4590 volume:13 year:2023 number:11 pages:4578-4590 |
sourceStr |
In Acta Pharmaceutica Sinica B 13(2023), 11, Seite 4578-4590 volume:13 year:2023 number:11 pages:4578-4590 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion Therapeutics. Pharmacology |
isfreeaccess_bool |
true |
container_title |
Acta Pharmaceutica Sinica B |
authorswithroles_txt_mv |
Xiaodong Zeng @@aut@@ Yuqin Liao @@aut@@ Xue Qiao @@aut@@ Ke Liang @@aut@@ Qiusi Luo @@aut@@ Mingbo Deng @@aut@@ Yishen Liu @@aut@@ Weijing Zhang @@aut@@ Xuechuan Hong @@aut@@ Yuling Xiao @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
670211095 |
id |
DOAJ09682509X |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ09682509X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413162815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.apsb.2023.07.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09682509X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf3027c07a4ab4913ada166c4a6276470</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiaodong Zeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel NIR-II fluorescent probes for biliary atresia imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biliary atresia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorescence imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second near-infrared window</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Early diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatobiliary excretion</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuqin Liao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xue Qiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ke Liang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qiusi Luo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mingbo Deng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yishen Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weijing Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xuechuan Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuling Xiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Pharmaceutica Sinica B</subfield><subfield code="d">Elsevier, 2013</subfield><subfield code="g">13(2023), 11, Seite 4578-4590</subfield><subfield code="w">(DE-627)670211095</subfield><subfield code="w">(DE-600)2631779-5</subfield><subfield code="x">22113843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:4578-4590</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.apsb.2023.07.005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2211383523002551</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2211-3835</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2023</subfield><subfield code="e">11</subfield><subfield code="h">4578-4590</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Xiaodong Zeng |
spellingShingle |
Xiaodong Zeng misc RM1-950 misc Biliary atresia misc Fluorescence imaging misc Second near-infrared window misc Early diagnosis misc Hepatobiliary excretion misc Therapeutics. Pharmacology Novel NIR-II fluorescent probes for biliary atresia imaging |
authorStr |
Xiaodong Zeng |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)670211095 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
22113843 |
topic_title |
RM1-950 Novel NIR-II fluorescent probes for biliary atresia imaging Biliary atresia Fluorescence imaging Second near-infrared window Early diagnosis Hepatobiliary excretion |
topic |
misc RM1-950 misc Biliary atresia misc Fluorescence imaging misc Second near-infrared window misc Early diagnosis misc Hepatobiliary excretion misc Therapeutics. Pharmacology |
topic_unstemmed |
misc RM1-950 misc Biliary atresia misc Fluorescence imaging misc Second near-infrared window misc Early diagnosis misc Hepatobiliary excretion misc Therapeutics. Pharmacology |
topic_browse |
misc RM1-950 misc Biliary atresia misc Fluorescence imaging misc Second near-infrared window misc Early diagnosis misc Hepatobiliary excretion misc Therapeutics. Pharmacology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Acta Pharmaceutica Sinica B |
hierarchy_parent_id |
670211095 |
hierarchy_top_title |
Acta Pharmaceutica Sinica B |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)670211095 (DE-600)2631779-5 |
title |
Novel NIR-II fluorescent probes for biliary atresia imaging |
ctrlnum |
(DE-627)DOAJ09682509X (DE-599)DOAJf3027c07a4ab4913ada166c4a6276470 |
title_full |
Novel NIR-II fluorescent probes for biliary atresia imaging |
author_sort |
Xiaodong Zeng |
journal |
Acta Pharmaceutica Sinica B |
journalStr |
Acta Pharmaceutica Sinica B |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
container_start_page |
4578 |
author_browse |
Xiaodong Zeng Yuqin Liao Xue Qiao Ke Liang Qiusi Luo Mingbo Deng Yishen Liu Weijing Zhang Xuechuan Hong Yuling Xiao |
container_volume |
13 |
class |
RM1-950 |
format_se |
Elektronische Aufsätze |
author-letter |
Xiaodong Zeng |
doi_str_mv |
10.1016/j.apsb.2023.07.005 |
author2-role |
verfasserin |
title_sort |
novel nir-ii fluorescent probes for biliary atresia imaging |
callnumber |
RM1-950 |
title_auth |
Novel NIR-II fluorescent probes for biliary atresia imaging |
abstract |
Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. |
abstractGer |
Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. |
abstract_unstemmed |
Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
11 |
title_short |
Novel NIR-II fluorescent probes for biliary atresia imaging |
url |
https://doi.org/10.1016/j.apsb.2023.07.005 https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470 http://www.sciencedirect.com/science/article/pii/S2211383523002551 https://doaj.org/toc/2211-3835 |
remote_bool |
true |
author2 |
Yuqin Liao Xue Qiao Ke Liang Qiusi Luo Mingbo Deng Yishen Liu Weijing Zhang Xuechuan Hong Yuling Xiao |
author2Str |
Yuqin Liao Xue Qiao Ke Liang Qiusi Luo Mingbo Deng Yishen Liu Weijing Zhang Xuechuan Hong Yuling Xiao |
ppnlink |
670211095 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.apsb.2023.07.005 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T22:30:37.473Z |
_version_ |
1803598784075137024 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ09682509X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413162815.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.apsb.2023.07.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ09682509X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf3027c07a4ab4913ada166c4a6276470</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Xiaodong Zeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Novel NIR-II fluorescent probes for biliary atresia imaging</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Biliary atresia is a rare infant disease that predisposes patients to liver transplantation and death if not treated in time. However, early diagnosis is challenging because the clinical manifestations and laboratory tests of biliary atresia overlap with other cholestatic diseases. Therefore, it is very important to develop a simple, safe and reliable method for the early diagnosis of biliary atresia. Herein, a novel NIR-II fluorescence probe, HZL2, with high quantum yield, excellent biocompatibility, low cytotoxicity and rapid excretion through the liver and gallbladder was developed based on the oil/water partition coefficient and permeability. A simple fecal sample after injection of HZL2 can be used to efficiently identify the success of the mouse model of biliary atresia for the first time, allowing for an early diagnosis of the disease. This study not only developed a simple and safe method for the early diagnosis of biliary atresia with great potential in clinical translation but also provides a research tool for the development of pathogenesis and therapeutic medicines for biliary atresia.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biliary atresia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorescence imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second near-infrared window</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Early diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hepatobiliary excretion</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuqin Liao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xue Qiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ke Liang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Qiusi Luo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mingbo Deng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yishen Liu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weijing Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Xuechuan Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuling Xiao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Pharmaceutica Sinica B</subfield><subfield code="d">Elsevier, 2013</subfield><subfield code="g">13(2023), 11, Seite 4578-4590</subfield><subfield code="w">(DE-627)670211095</subfield><subfield code="w">(DE-600)2631779-5</subfield><subfield code="x">22113843</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:4578-4590</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.apsb.2023.07.005</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f3027c07a4ab4913ada166c4a6276470</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2211383523002551</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2211-3835</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2023</subfield><subfield code="e">11</subfield><subfield code="h">4578-4590</subfield></datafield></record></collection>
|
score |
7.400218 |